NCT07465029

A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain

Observational Retrospective Study on Incidence, First-line Treatment Patterns, and Clinical Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain Using the BIG-PAC® Database

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,300 (estimated)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to understand the incidence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) and describing real-world first-line treatment patterns, healthcare resource utilization, and associated clinical outcomes in adult patients with TD LR-MDS in Spain

Conditions

• Lower-risk Myelodysplastic Syndromes (TD LR-MDS)

Interventions

Type	Name	Description
DRUG	Erythropoiesis-stimulating agents (ESAs)	According to the product label
BIOLOGICAL	Luspatercept	According to the product label
DRUG	Lenalidomide	According to the product label
DRUG	Hypomethylating agents (HMAs)	According to the product label
BIOLOGICAL	Reb blood cell transfusion	According to the product label

Timeline

• Start date: 2026-02-02
• Primary completion: 2026-03-31
• Completion: 2026-05-31
• First posted: 2026-03-11
• Last updated: 2026-03-11

Locations

1 site across 1 country: Spain

Regulatory

• FDA-regulated drug study